Physician profile
Nathan C Trentham
NPI 1134185358
$404,375.52
in general payments reported to CMS, 2019-2025
59 companies · $83K in 2025
The $83K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52K · 2020: $34K · 2021: $29K · 2022: $65K · 2023: $79K · 2024: $61K · 2025: $83K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $183K · Travel and Lodging: $16K · Consulting Fee: $14K · Food and Beverage: $9,903 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $183,172.00 |
| Travel and Lodging | $16,151.83 |
| Consulting Fee | $14,252.50 |
| Food and Beverage | $9,903.42 |
| Education | $130.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $325,152.98 | 2019-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $28,336.41 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Esperion Therapeutics, INC. | $17,279.54 | 2020-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $10,116.61 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $6,386.29 | 2020-2025 | Verquvo, Belsomra, Steglatro |
| Regeneron Healthcare Solutions, INC. | $4,418.36 | 2019-2025 | Evkeeza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,093.58 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $1,836.63 | 2019-2025 | |
| Novo Nordisk INC | $1,209.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $872.50 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $659.88 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $628.12 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $585.49 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $523.64 | 2019-2025 | Farxiga, Airsupra, Brilinta |
| Janssen Pharmaceuticals, INC | $384.05 | 2019-2022 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Trentham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.